Objective: To discuss the clinical significance of Federation International of Gynecology and Obstetrics (FIGO) 2009 staging I and its prognostic related factors in endometrial carcinoma.
Methods: A retrospective analysis was carried out on 233 cases with FIGO 2009 staging I endometrial carcinoma who were admitted to Department of Obstetrics and Gynecology, Peking University People's Hospital from Dec. 1998 to Dec. 2009 and were carried with complete staging operation then compared with FIGO 1988 staging. All follow-up data were complete.
Results: Of the 233 cases, including FIGO 1988 staging I a 41 cases, I b 146 cases, I c 29 cases and II a 17 cases. The univariate analysis revealed that there were no significant difference between staging I a and I b group in histological grade, pathological type, intravascular vessel cancer embolus, the expression of ER, PR, postoperative chemotherapy or postoperative chemoradiotherapy (all P > 0.05). The univariate analysis revealed that there were no significant difference between staging I and II a group in histological grade, pathological type, intravascular vessel cancer embolus, the depth of myometrial invasion, the expression of ER and PR postoperative chemotherapy or postoperative chemoradiotherapy (all P > 0.05).
Conclusion: FIGO 2009 staging I in endometrial carcinoma is more consistent with the patient's clinical status than that in FIGO 1988 stage I and II a.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Re-evaluating prognostic factors for cervical cancer with lymph node metastasis: a Japanese multicenter cohort study based on FIGO 2018.
Int J Clin Oncol
January 2025
Department of Gynecology and Obstetrics, Kyoto University Graduate School of Medicine, 54 Kawahara-Cho, Shogoin, Sakyo-ku, Kyoto, 606-8507, Japan.
Background: In 2018, the International Federation of Gynecology and Obstetrics (FIGO) revised its cervical cancer staging system to enhance clinical relevance, notably by categorizing lymph node metastases (LNM) as an independent stage IIIC. This multicenter study evaluates the prognostic implications of the FIGO 2018 classification within a Japanese cohort.
Methods: This study included 1468 patients with cervical cancer.
Impact of the Number of Positive Pelvic Lymph Nodes on Risk of Para-Aortic Recurrence in Patients with Clinically Early Cervical Cancer Treated by a Radical Hysterectomy and Pelvic Lymphadenectomy.
Cancers (Basel)
December 2024
Department of Gynecological Oncology, Centre for Gynecologic Oncology Amsterdam (C.G.O.A.), Amsterdam University Medical Center, 1081 HV Amsterdam, The Netherlands.
Background: Guidelines recommend the extension of the pelvic radiotherapy volume to the para-aortic region in locally advanced cervical cancer and ≥3 suspicious pelvic lymph nodes (PLN) on imaging. Whether this recommendation is also valid for clinically early stages is uncertain. The objective of this study was to investigate the para-aortic (PAO) lymph node recurrence rate in patients with early-stage cervical cancer, ≥3 metastatic PLN, and negative common iliac nodes after a radical hysterectomy followed by pelvic (chemo)radiotherapy without extension to the PAO region.
View Article and Find Full Text PDFFIGO 2023 staging system predicts not only survival outcome but also recurrence pattern in corpus-confined endometrial cancer patients.
Taiwan J Obstet Gynecol
January 2025
Department of Obstetrics and Gynecology, Taipei Veterans General Hospital, Taipei, Taiwan; School of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan; Institute of Clinical Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan. Electronic address:
Objective: Approximately 10-15 % of endometrial cancer patients with tumors confined to the uterus (FIGO 2009 stage I) demonstrate recurrence and the oncologic outcomes are highly related to recurrence patterns. This study aimed to verify whether the FIGO 2023 staging system could discriminate outcomes.
Materials And Methods: Between January 2010 and March 2019, 536 FIGO 2009 stage I patients were eligible for this retrospective cohort study.
Should all cervical cancer patients with positive lymph node receive definitive radiotherapy: a population-based comparative study.
Arch Gynecol Obstet
January 2025
Department of Gynecology, Cancer Hospital of China Medical University, Liaoning Cancer Hospital & Institute, Cancer Hospital of Dalian University of Technology, No.44, Xiaoheyan Road, Dadong District, Shenyang, Liaoning, 110042, People's Republic of China.
Objective: The optimal initial management strategy for cervical cancer with lymph node metastases (LNM) remains a topic of ongoing debate. This study aimed to explore the correlation between surgery followed by postoperative radiotherapy (PORT) and definitive radiotherapy (RT), as well as their impact on the prognosis of patients with LNM.
Methods: Patients with positive lymph nodes (PLNs) in 2009 FIGO stage I-III cervical cancer were selected from SEER database.
This randomized phase III trial aimed to determine whether treatment with cisplatin and volume-directed radiation followed by carboplatin and paclitaxel for four cycles (chemoradiotherapy [C-RT]) increased recurrence-free survival (RFS) and overall survival (OS) when compared with carboplatin and paclitaxel for six cycles (chemotherapy [CT]) in locally advanced endometrial cancer (UC). Previously reported results showed that C-RT did not improve RFS compared with CT. Here we report the final OS analysis.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!